Tarsus Pharmaceuticals, Inc. 8-K

What Happened

• On February 23, 2026, Tarsus Pharmaceuticals, Inc. (TARS) filed a Form 8-K under Item 2.02 to furnish a press release that reports the company’s results of operations for the year ended December 31, 2025. The press release is attached as Exhibit 99.1 to the filing and the submission includes the company’s interactive XBRL cover page (Exhibit 104). The report was signed by Jeffrey S. Farrow, Chief Financial Officer and Chief Strategy Officer.

Key Details

• Filing date: February 23, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: year ended December 31, 2025 (results presented in attached press release, Exhibit 99.1).
• Exhibits included: 99.1 (Press Release dated Feb 23, 2026) and 104 (Cover Page Interactive Data / XBRL).
• The 8-K furnishes the press release (information is provided as furnished, not separately "filed" for certain SEC liabilities).

Why It Matters

• This 8-K is the company’s official disclosure of its full-year 2025 financial results; investors should read the attached press release and XBRL data to see the detailed figures for revenue, net income (or loss), cash position, and any commentary on performance or guidance.
• Those facts can affect valuation, analyst models, and near-term trading decisions—so review the exhibits and any subsequent SEC filings or investor materials for follow-up details.